CA
NZ
UK
AU
IND
US
…
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Vertex Pharmaceuticals develops and commercializes therapies for cystic fibrosis and is advancing gene‑editing and other rare‑disease programs via internal R&D and partnerships such as with CRISPR Therapeutics. Long-term growth may be driven by continued CF penetration and label expansion, global market access, and upside from gene‑editing and cell‑therapy programs, making it appealing for investors seeking a leading biotech with recurring revenues.
Major risks include dependence on the CF franchise for most revenue, clinical and regulatory uncertainty for experimental programs, and pricing, patent or reimbursement pressures.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 4643.20M | 248.50M | 4379.80M | 4232.40M | 2730.40M |
| Net income | 3953.20M | -535.60M | 3619.60M | 3322.00M | 2342.10M |
| Selling general administrative | 1753.10M | 1464.30M | 1136.60M | 887.20M | 840.10M |
| Gross profit | 10267.50M | 9489.60M | 8607.00M | 7850.40M | 6670.20M |
| Reconciled depreciation | 209.80M | 207.20M | 181.30M | 148.30M | 125.60M |
| Ebit | 4656.50M | 280.50M | 4423.90M | 4307.40M | 2782.10M |
| Ebitda | 4863.70M | 486.30M | 4605.20M | 4345.20M | 2788.80M |
| Depreciation and amortization | 207.20M | 205.80M | 181.30M | 37.80M | 6.70M |
| Non operating income net other | - | - | - | -20.20M | 9.80M |
| Operating income | 4760.70M | -232.90M | 3832.00M | 4307.40M | 2782.10M |
| Other operating expenses | 7313.90M | 11253.00M | 6037.20M | 4565.30M | 4795.40M |
| Interest expense | 13.30M | 30.60M | 44.10M | 54.80M | 61.50M |
| Tax provision | 690.00M | 784.10M | 760.20M | 910.40M | 388.30M |
| Interest income | 490.90M | 598.10M | 614.70M | 144.60M | 4.90M |
| Net interest income | 477.60M | 567.50M | 570.60M | 89.80M | -56.60M |
| Non recurring | - | - | - | 115.50M | - |
| Income tax expense | 690.00M | 784.10M | 760.20M | 910.40M | 388.30M |
| Total revenue | 12074.60M | 11020.10M | 9869.20M | 8930.70M | 7574.40M |
| Total operating expenses | 5506.80M | 9722.50M | 4775.00M | 3485.00M | 3891.20M |
| Cost of revenue | 1807.10M | 1530.50M | 1262.20M | 1080.30M | 904.20M |
| Total other income expense net | -117.50M | 481.40M | 547.80M | -75.00M | -51.70M |
| Net income from continuing ops | 3953.20M | -535.60M | 3619.60M | 3322.00M | 2342.10M |
| Net income applicable to common shares | - | - | - | 3322.00M | 2342.10M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 26142.80M | 22533.20M | 22730.20M | 18150.90M | 13432.50M |
| Intangible assets | 424.20M | 825.90M | 839.90M | 603.60M | 400.00M |
| Other current assets | 850.30M | 665.70M | 620.50M | 74.40M | 187.20M |
| Total liab | 7477.00M | 6123.60M | 5149.80M | 4238.20M | 3332.50M |
| Total stockholder equity | 18665.80M | 16409.60M | 17580.40M | 13912.70M | 10100.00M |
| Other current liab | 3144.90M | 2691.40M | 2928.50M | 1877.70M | 1460.00M |
| Common stock | 2.50M | 2.60M | 2.60M | 2.60M | 2.50M |
| Capital stock | 2.50M | 2.60M | 2.60M | 2.60M | 2.50M |
| Retained earnings | 13560.00M | 9606.80M | 10142.40M | 6522.80M | 3200.80M |
| Other liab | - | - | - | 685.80M | 902.20M |
| Good will | 1088.00M | 1088.00M | 1088.00M | 1088.00M | 1402.20M |
| Other assets | - | - | - | 1422.70M | 986.90M |
| Cash | 5087.80M | 4569.60M | 10372.30M | 10504.00M | 6795.00M |
| Total current liabilities | 3861.20M | 3564.60M | 3547.40M | 2430.60M | 1873.60M |
| Current deferred revenue | 171.80M | 206.80M | 170.30M | 159.60M | 171.70M |
| Net debt | -1205.30M | -2820.10M | -9563.90M | -9943.00M | -6238.30M |
| Short term debt | 82.80M | 92.30M | 83.70M | 89.40M | 46.90M |
| Short long term debt total | 3882.50M | 1749.50M | 808.40M | 561.00M | 556.70M |
| Other stockholder equity | 5119.20M | 6672.40M | 7449.70M | 7386.50M | 6880.80M |
| Property plant equipment | - | - | - | 1455.80M | 1094.10M |
| Total current assets | 11201.00M | 9596.40M | 14144.20M | 12681.30M | 9014.80M |
| Long term investments | 5712.30M | 5107.90M | 2497.80M | - | - |
| Net tangible assets | - | - | - | 12221.10M | 8697.80M |
| Short term investments | 1523.30M | 1546.30M | 849.20M | 274.50M | 729.90M |
| Net receivables | 2052.80M | 1609.40M | 1563.40M | 1442.20M | 1136.80M |
| Inventory | 1686.80M | 1205.40M | 738.80M | 460.60M | 353.10M |
| Accounts payable | 461.70M | 413.00M | 364.90M | 303.90M | 195.00M |
| Accumulated other comprehensive income | -15.90M | 127.80M | -14.30M | 0.80M | 15.90M |
| Common stock total equity | - | - | - | 2.60M | 2.50M |
| Retained earnings total equity | - | - | - | 6522.80M | 3200.80M |
| Non currrent assets other | 1142.40M | 999.30M | 796.70M | 1422.70M | 986.90M |
| Non current assets total | 14941.80M | 12936.80M | 8586.00M | 5469.60M | 4417.70M |
| Capital lease obligations | 2030.50M | 1749.50M | 808.40M | 471.60M | 556.70M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -483.10M | -3770.00M | -2079.60M | 227.30M | -28.90M |
| Change to liabilities | - | - | - | 1162.20M | 354.10M |
| Total cashflows from investing activities | -945.40M | -3770.00M | - | -321.10M | -340.90M |
| Net borrowings | -5.40M | -33.60M | - | -85.50M | -24.40M |
| Total cash from financing activities | -2261.30M | -1494.90M | -562.20M | -67.70M | -1478.00M |
| Change to operating activities | - | - | - | 715.00M | 230.40M |
| Net income | 3953.20M | -535.60M | 3619.60M | 3322.00M | 2342.10M |
| Change in cash | 515.60M | -5800.10M | -139.70M | 3711.90M | 811.20M |
| Begin period cash flow | 4572.20M | 10372.30M | 10512.00M | 6800.10M | 5988.90M |
| End period cash flow | 5087.80M | 4572.20M | 10372.30M | 10512.00M | 6800.10M |
| Total cash from operating activities | 3631.40M | -492.60M | 3537.30M | 4129.90M | 2643.50M |
| Depreciation | 209.80M | 207.20M | 181.30M | 148.30M | 125.60M |
| Other cashflows from investing activities | -24.70M | -241.70M | - | -343.70M | -77.00M |
| Dividends paid | - | - | - | - | 102.00M |
| Change to inventory | -524.20M | -517.30M | -322.90M | -136.40M | -92.80M |
| Change to account receivables | -347.30M | -99.30M | -84.10M | -358.60M | -274.70M |
| Sale purchase of stock | -2017.40M | -1177.10M | -427.60M | -172.00M | -1561.30M |
| Other cashflows from financing activities | -366.20M | -398.80M | -224.30M | 3.50M | 130.30M |
| Change to netincome | - | - | - | 445.60M | 452.70M |
| Capital expenditures | 437.60M | 297.70M | 258.40M | 204.70M | 235.00M |
| Change receivables | - | - | - | -358.60M | -274.70M |
| Cash flows other operating | - | - | - | -453.20M | -263.50M |
| Cash and cash equivalents changes | - | - | - | 3741.10M | 824.60M |
| Change in working capital | -1199.10M | -514.80M | -265.70M | 340.80M | -105.20M |
| Stock based compensation | 685.90M | 698.50M | 581.20M | 491.30M | 441.40M |
| Other non cash items | 492.40M | 0.90M | -42.60M | 103.40M | -5.80M |
| Free cash flow | 3193.80M | -790.30M | 3278.90M | 3925.20M | 2408.50M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Inc |
3.54 0.68% |
521.03 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| NVO Novo Nordisk A/S |
-0.46 1.18% |
38.67 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| REGN Regeneron Pharmaceuticals Inc |
8.43 1.04% |
816.10 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
| CMXHF CSL Limited |
-1.90 1.39% |
135.00 | - | 18.87 | 3.71 | 3.96 | 4.35 | 10.84 |
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Jeffrey Marc Leiden M.D., Ph.D. | Exec. Chairman | 1956 |
| Dr. Reshma Kewalramani FASN, M.D. | CEO, Pres & Director | 1973 |
| Mr. Charles F. Wagner Jr. | Exec. VP & CFO | 1968 |
| Mr. Stuart A. Arbuckle B.Sc. | Exec. VP & COO | 1966 |
| Dr. Ourania Tatsis Ph.D. | Exec. VP and Chief Regulatory & Quality Officer | 1971 |
| Ms. Kristen C. Ambrose | Chief Accounting Officer & SVP of Accounting, Tax, Treasury, Strategic Sourcing & Corp. Services | 1977 |
| Dr. David M. Altshuler M.D., Ph.D. | Exec. VP of Global Research & Chief Scientific Officer | 1965 |
| Mr. Mike Tirozzi | SVP and Chief Information & Data Officer | NA |
| Susie Lisa | Sr. VP of Investor Relations | NA |
| Mr. Damian W. Wilmot Esq. | Sr. VP, Chief Risk and Compliance Officer | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...